170 related articles for article (PubMed ID: 38761968)
1. Deriving acceptable limits for non-mutagenic impurities in medicinal products - Durational adjustments.
Kenyon MO; Martin M; Martin EA; Brandstetter S; Wegesser T; Greene N; Harvey J
Regul Toxicol Pharmacol; 2024 Jun; 150():105644. PubMed ID: 38761968
[TBL] [Abstract][Full Text] [Related]
2. Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.
Harvey J; Fleetwood A; Ogilvie R; Teasdale A; Wilcox P; Spanhaak S
Regul Toxicol Pharmacol; 2017 Mar; 84():116-123. PubMed ID: 28038978
[TBL] [Abstract][Full Text] [Related]
3. New limits proposed for the management of non-mutagenic impurities.
Slikkerveer A; Doehr O; Claude N; Hutchinson R; Harvey J; Spanhaak S
Regul Toxicol Pharmacol; 2024 Jun; 150():105647. PubMed ID: 38777301
[TBL] [Abstract][Full Text] [Related]
4. Analysis of non-mutagenic substances in the context of drug impurity assessment - Few are potent toxicants.
Hasselgren C; Kenyon M; Anger LT; Cornwell P; Watt E; Bercu J
Regul Toxicol Pharmacol; 2024 Jun; 150():105645. PubMed ID: 38761967
[TBL] [Abstract][Full Text] [Related]
5. Non-mutagenic impurities - Recent industry experience of using dose durational limits in drug development.
Lortie A; Martin EA; Arnot K
Regul Toxicol Pharmacol; 2024 Feb; 147():105559. PubMed ID: 38145838
[TBL] [Abstract][Full Text] [Related]
6. Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
Bercu JP; Galloway SM; Parris P; Teasdale A; Masuda-Herrera M; Dobo K; Heard P; Kenyon M; Nicolette J; Vock E; Ku W; Harvey J; White A; Glowienke S; Martin EA; Custer L; Jolly RA; Thybaud V
Regul Toxicol Pharmacol; 2018 Apr; 94():172-182. PubMed ID: 29408293
[TBL] [Abstract][Full Text] [Related]
7. Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey.
Mitra MS; Datta K; Hutchinson R; Nicolette JJ; Pettersen JC; Wegesser TC; Bercu JP
Regul Toxicol Pharmacol; 2021 Jun; 122():104895. PubMed ID: 33610610
[TBL] [Abstract][Full Text] [Related]
8. Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities.
Kovarich S; Cappelli CI
Methods Mol Biol; 2022; 2425():537-560. PubMed ID: 35188646
[TBL] [Abstract][Full Text] [Related]
9. Qualification of impurities based on metabolite data.
Weidolf L; Andersson T; Bercu JP; Brink A; Glowienke S; Harvey J; Hayes MA; Jacques P; Lu C; Manevski N; Muster W; Nudelman R; Ogilvie R; Ottosson J; Teasdale A; Trela B
Regul Toxicol Pharmacol; 2020 Feb; 110():104524. PubMed ID: 31734179
[TBL] [Abstract][Full Text] [Related]
10. Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates.
Gong HH; Ihle N; Jones MT; Kelly K; Kott L; Raglione T; Whitlock S; Zhang Q; Zheng J
AAPS PharmSciTech; 2018 Apr; 19(3):971-977. PubMed ID: 29302872
[TBL] [Abstract][Full Text] [Related]
11. International Conference on Harmonisation; revised guidance on Q3B(R) Impurities in New Drug Products; Availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Nov; 68(220):64628-9. PubMed ID: 14619944
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Extractable Elements from Elastomers.
Paskiet D; Kraft C; Tullo E; Hunter J; Zurbriggen D
PDA J Pharm Sci Technol; 2019; 73(1):83-91. PubMed ID: 30030347
[TBL] [Abstract][Full Text] [Related]
13. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
14. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
[TBL] [Abstract][Full Text] [Related]
15. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
16. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
[TBL] [Abstract][Full Text] [Related]
17. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
Pokar D; Rajput N; Sengupta P
Int J Pharm; 2020 Feb; 576():119018. PubMed ID: 31911117
[TBL] [Abstract][Full Text] [Related]
18. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
19. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
Jenke D; Carlson T
PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
[TBL] [Abstract][Full Text] [Related]
20. International Conference on Harmonisation; revised guidance on Q3A impurities in new drug substances; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Feb; 68(28):6924-5. PubMed ID: 12583358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
